Your browser doesn't support javascript.
Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021.
Wulf Hanson, Sarah; Abbafati, Cristiana; Aerts, Joachim G; Al-Aly, Ziyad; Ashbaugh, Charlie; Ballouz, Tala; Blyuss, Oleg; Bobkova, Polina; Bonsel, Gouke; Borzakova, Svetlana; Buonsenso, Danilo; Butnaru, Denis; Carter, Austin; Chu, Helen; De Rose, Cristina; Diab, Mohamed Mustafa; Ekbom, Emil; El Tantawi, Maha; Fomin, Victor; Frithiof, Robert; Gamirova, Aysylu; Glybochko, Petr V; Haagsma, Juanita A; Haghjooy Javanmard, Shaghayegh; Hamilton, Erin B; Harris, Gabrielle; Heijenbrok-Kal, Majanka H; Helbok, Raimund; Hellemons, Merel E; Hillus, David; Huijts, Susanne M; Hultström, Michael; Jassat, Waasila; Kurth, Florian; Larsson, Ing-Marie; Lipcsey, Miklós; Liu, Chelsea; Loflin, Callan D; Malinovschi, Andrei; Mao, Wenhui; Mazankova, Lyudmila; McCulloch, Denise; Menges, Dominik; Mohammadifard, Noushin; Munblit, Daniel; Nekliudov, Nikita A; Ogbuoji, Osondu; Osmanov, Ismail M; Peñalvo, José L; Petersen, Maria Skaalum.
  • Wulf Hanson S; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Abbafati C; Department of Juridical and Economic Studies, La Sapienza University, Rome, Italy.
  • Aerts JG; Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Al-Aly Z; John T. Milliken Department of Internal Medicine, Washington University in St Louis, St Louis, Missouri.
  • Ashbaugh C; Clinical Epidemiology Center, US Department of Veterans Affairs, St Louis, Missouri.
  • Ballouz T; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Blyuss O; Epidemiology, Biostatistics, and Prevention Institute, University of Zürich, Zurich, Switzerland.
  • Bobkova P; Wolfson Institute of Population Health, Queen Mary University of London, London, England.
  • Bonsel G; Department of Pediatrics and Pediatric Infectious Diseases, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Borzakova S; Clinical Medicine (Pediatric Profile), I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Buonsenso D; EuroQol Research Foundation, Rotterdam, the Netherlands.
  • Butnaru D; Pirogov Russian National Research Medical University, Moscow.
  • Carter A; Research Institute for Healthcare Organization and Medical Management, Moscow Healthcare Department, Moscow, Russia.
  • Chu H; Department of Woman and Child Health and Public Health, Agostino Gemelli University Polyclinic IRCCS, Rome, Italy.
  • De Rose C; Global Health Research Institute, Catholic University of Sacred Heart, Rome, Italy.
  • Diab MM; I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Ekbom E; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • El Tantawi M; Department of Medicine, University of Washington, Seattle.
  • Fomin V; Department of Woman and Child Health and Public Health, Agostino Gemelli University Polyclinic IRCCS, Rome, Italy.
  • Frithiof R; Center for Policy Impact in Global Health, Duke University, Durham, North Carolina.
  • Gamirova A; Department of Surgery, Duke University, Durham, North Carolina.
  • Glybochko PV; Uppsala University Hospital, Uppsala, Sweden.
  • Haagsma JA; Pediatric Dentistry and Dental Public Health Department, Alexandria University, Alexandria, Egypt.
  • Haghjooy Javanmard S; Rector's Office, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Hamilton EB; Department of Surgical Sciences, Anesthesiology, and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.
  • Harris G; Clinical Medicine (General Medicine Profile), I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Heijenbrok-Kal MH; Administration Department, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Helbok R; Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Hellemons ME; Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Hillus D; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Huijts SM; School of Nursing, Duke University, Durham, North Carolina.
  • Hultström M; Department of Rehabilitation Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Jassat W; Neurorehabilitation, Rijndam Rehabilitation, Rotterdam, the Netherlands.
  • Kurth F; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
  • Larsson IM; Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Lipcsey M; Department of Infectious Diseases and Respiratory Medicine, Charité Medical University Berlin, Berlin, Germany.
  • Liu C; Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Loflin CD; Department of Surgical Sciences, Anesthesiology, and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.
  • Malinovschi A; Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
  • Mao W; Department of Public Health Surveillance and Response, National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Mazankova L; Department of Infectious Diseases and Respiratory Medicine, Charité University Medical Center Berlin, Berlin, Germany.
  • McCulloch D; Department of Clinical Research and Tropical Medicine, Bernhard-Nocht Institute of Tropical Medicine, Hamburg, Germany.
  • Menges D; Department of Surgical Sciences, Anesthesiology, and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.
  • Mohammadifard N; Department of Surgical Sciences, Anesthesiology, and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.
  • Munblit D; Department of Epidemiology, Harvard University, Boston, Massachusetts.
  • Nekliudov NA; School of Nursing, Duke University, Durham, North Carolina.
  • Ogbuoji O; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Osmanov IM; Center for Policy Impact in Global Health, Duke University, Durham, North Carolina.
  • Peñalvo JL; Duke Global Health Institute, Duke University, Durham, North Carolina.
  • Petersen MS; Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare of the Russian Federation, Moscow.
JAMA ; 328(16): 1604-1615, 2022 10 25.
Article in English | MEDLINE | ID: covidwho-2058991
ABSTRACT
Importance Some individuals experience persistent symptoms after initial symptomatic SARS-CoV-2 infection (often referred to as Long COVID).

Objective:

To estimate the proportion of males and females with COVID-19, younger or older than 20 years of age, who had Long COVID symptoms in 2020 and 2021 and their Long COVID symptom duration. Design, Setting, and

Participants:

Bayesian meta-regression and pooling of 54 studies and 2 medical record databases with data for 1.2 million individuals (from 22 countries) who had symptomatic SARS-CoV-2 infection. Of the 54 studies, 44 were published and 10 were collaborating cohorts (conducted in Austria, the Faroe Islands, Germany, Iran, Italy, the Netherlands, Russia, Sweden, Switzerland, and the US). The participant data were derived from the 44 published studies (10 501 hospitalized individuals and 42 891 nonhospitalized individuals), the 10 collaborating cohort studies (10 526 and 1906), and the 2 US electronic medical record databases (250 928 and 846 046). Data collection spanned March 2020 to January 2022. Exposures Symptomatic SARS-CoV-2 infection. Main Outcomes and

Measures:

Proportion of individuals with at least 1 of the 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after SARS-CoV-2 infection in 2020 and 2021, estimated separately for hospitalized and nonhospitalized individuals aged 20 years or older by sex and for both sexes of nonhospitalized individuals younger than 20 years of age.

Results:

A total of 1.2 million individuals who had symptomatic SARS-CoV-2 infection were included (mean age, 4-66 years; males, 26%-88%). In the modeled estimates, 6.2% (95% uncertainty interval [UI], 2.4%-13.3%) of individuals who had symptomatic SARS-CoV-2 infection experienced at least 1 of the 3 Long COVID symptom clusters in 2020 and 2021, including 3.2% (95% UI, 0.6%-10.0%) for persistent fatigue with bodily pain or mood swings, 3.7% (95% UI, 0.9%-9.6%) for ongoing respiratory problems, and 2.2% (95% UI, 0.3%-7.6%) for cognitive problems after adjusting for health status before COVID-19, comprising an estimated 51.0% (95% UI, 16.9%-92.4%), 60.4% (95% UI, 18.9%-89.1%), and 35.4% (95% UI, 9.4%-75.1%), respectively, of Long COVID cases. The Long COVID symptom clusters were more common in women aged 20 years or older (10.6% [95% UI, 4.3%-22.2%]) 3 months after symptomatic SARS-CoV-2 infection than in men aged 20 years or older (5.4% [95% UI, 2.2%-11.7%]). Both sexes younger than 20 years of age were estimated to be affected in 2.8% (95% UI, 0.9%-7.0%) of symptomatic SARS-CoV-2 infections. The estimated mean Long COVID symptom cluster duration was 9.0 months (95% UI, 7.0-12.0 months) among hospitalized individuals and 4.0 months (95% UI, 3.6-4.6 months) among nonhospitalized individuals. Among individuals with Long COVID symptoms 3 months after symptomatic SARS-CoV-2 infection, an estimated 15.1% (95% UI, 10.3%-21.1%) continued to experience symptoms at 12 months. Conclusions and Relevance This study presents modeled estimates of the proportion of individuals with at least 1 of 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after symptomatic SARS-CoV-2 infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Insufficiency / Cognition Disorders / Fatigue / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Reviews Topics: Long Covid Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Language: English Journal: JAMA Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Insufficiency / Cognition Disorders / Fatigue / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Reviews Topics: Long Covid Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Language: English Journal: JAMA Year: 2022 Document Type: Article